Nestlé divests its peanut allergy treatment business
Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company that specialises in the diagnosis and treatment of allergies. The transaction was closed upon signing.
Last year, Nestlé announced it would conduct a strategic review of Palforzia. It will now receive milestone payments and ongoing royalties from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said Nestlé is confident that Stallergenes Greer will take Palforzia forward, allowing Nestlé Health Science to focus on its strengths and growth drivers.
There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
APPEX 2027 is now open for registrations
APPEX 2027 registrations open for Australia's Processing and Packaging Expo, which is...
Facing the manufacturing workforce challenges of the future
Skills shortages persist as manufacturing workforce demand is expected to grow over 12% by 2035,...
Funding to help expand global demand for Victorian dairy
The Victorian Government has partnered with Dairy Australia on a program designed to help local...
